Abstract
Infusion of the antitumor necrosis factor-α chimeric monoclonal antibody infliximab can be associated with the development of severe infusion reactions (IR) during retreatment. We present the case of two rheumatoid arthritis patients with a history of severe acute IR to infliximab who subsequently underwent successful infusion using a prophylactic treatment with a combination of H1 and H2 receptor blockers, hydrocortisone, and diphenhydramine.
This is a preview of subscription content, log in via an institution to check access.
References
Cush JJ (2004) Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 30(2):237–255
Colombel J-F, Loftus EV Jr, Tremaine WJ, Sandborn WJ, Egan LJ, Harmsen WS et al (2004) The safety profile of infliximab in patients with Crohn's disease: the mayo clinic experience in 500 patients. Gastroenterology 126(1 suppl 1):19–31
Plevy S, Cheifetz A, Smedley M, Martin S, Reiter M, Leone G et al (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98(6):1315–1324
Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC (2004) Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 31(10):1912–1917
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549
Schaible TF (2000) Long term safety of infliximab. Can J Gastroenterol (14 suppl) C:29C–32C
Marone G, Granata F, Spadaro G, Genovese A, Triggiani M, Marone G (2003) The histamine–cytokine network in allergic inflammation. J Allergy Clin Immunol 112(4 suppl):S83–S88
Lin RY, Curry A, Pesola GR, Knight RJ, Lee H-S, Bakalchuk L et al (2000) Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 36(5):462–468
Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D et al (2002) Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 97(6):1408–1414
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Uthman, I., Touma, Z., El-Sayyad, J. et al. Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol 25, 540–541 (2006). https://doi.org/10.1007/s10067-005-0029-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0029-9